This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Jan 4;356(1):6-9.

doi: 10.1056/NEJMp068265.

Drugs and valvular heart disease

Affiliations

Affiliation

¹ Department of Pharmacology, Schools of Medicine and Pharmacy, National Institute of Mental Health Psychoactive Drug Screening Program at the University of North Carolina, Chapel Hill, USA.

PMID: 17202450
DOI: 10.1056/NEJMp068265

Comment

Drugs and valvular heart disease

Bryan L Roth. N Engl J Med. 2007.

. 2007 Jan 4;356(1):6-9.

doi: 10.1056/NEJMp068265.

Author

Affiliation

¹ Department of Pharmacology, Schools of Medicine and Pharmacy, National Institute of Mental Health Psychoactive Drug Screening Program at the University of North Carolina, Chapel Hill, USA.

PMID: 17202450
DOI: 10.1056/NEJMp068265

No abstract available

PubMed Disclaimer

Comment in

Dopamine agonists and valvular heart disease.
Sartiani L, Cerbai E, Mugelli A. Sartiani L, et al. N Engl J Med. 2007 Apr 19;356(16):1677-8; author reply 1678-80. N Engl J Med. 2007. PMID: 17447276 No abstract available.
Dopamine agonists and valvular heart disease.
Ziegler JL, Bukhman GY. Ziegler JL, et al. N Engl J Med. 2007 Apr 19;356(16):1677; author reply 1678-80. N Engl J Med. 2007. PMID: 17447277 No abstract available.
Dopamine agonists and valvular heart disease.
Kast RE, Altschuler EL. Kast RE, et al. N Engl J Med. 2007 Apr 19;356(16):1677; author reply 1678-80. N Engl J Med. 2007. PMID: 17447278 No abstract available.

Comment on

Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Schade R, et al. N Engl J Med. 2007 Jan 4;356(1):29-38. doi: 10.1056/NEJMoa062222. N Engl J Med. 2007. PMID: 17202453
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Zanettini R, et al. N Engl J Med. 2007 Jan 4;356(1):39-46. doi: 10.1056/NEJMoa054830. N Engl J Med. 2007. PMID: 17202454

Similar articles

Dopamine agonists and valvular heart disease.
Kast RE, Altschuler EL. Kast RE, et al. N Engl J Med. 2007 Apr 19;356(16):1677; author reply 1678-80. N Engl J Med. 2007. PMID: 17447278 No abstract available.
Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Schade R, et al. N Engl J Med. 2007 Jan 4;356(1):29-38. doi: 10.1056/NEJMoa062222. N Engl J Med. 2007. PMID: 17202453
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT. Pullan PT. Intern Med J. 2009 Apr;39(4):213-5. doi: 10.1111/j.1445-5994.2009.01916.x. Intern Med J. 2009. PMID: 19402858 No abstract available.
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A, Poewe W. Antonini A, et al. Lancet Neurol. 2007 Sep;6(9):826-9. doi: 10.1016/S1474-4422(07)70218-1. Lancet Neurol. 2007. PMID: 17706566 Review.
Drug-induced fibrotic valvular heart disease.
Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Bhattacharyya S, et al. Lancet. 2009 Aug 15;374(9689):577-85. doi: 10.1016/S0140-6736(09)60252-X. Lancet. 2009. PMID: 19683643 Review.

See all similar articles

Cited by

Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond.
Vandevelde M, Simoens A, Vandekerckhove B, Stevens C. Vandevelde M, et al. RSC Med Chem. 2024 Feb 21;15(3):998-1002. doi: 10.1039/d4md00043a. eCollection 2024 Mar 20. RSC Med Chem. 2024. PMID: 38516602 Free PMC article.
Beyond the Brain: Perinatal Exposure of Rats to Serotonin Enhancers Induces Long-Term Changes in the Jejunum and Liver.
Gračan R, Blažević SA, Brižić M, Hranilovic D. Gračan R, et al. Biomedicines. 2024 Feb 3;12(2):357. doi: 10.3390/biomedicines12020357. Biomedicines. 2024. PMID: 38397959 Free PMC article.
Making Sense of Psychedelics in the CNS.
Fordyce BA, Roth BL. Fordyce BA, et al. Int J Neuropsychopharmacol. 2024 Feb 1;27(2):pyae007. doi: 10.1093/ijnp/pyae007. Int J Neuropsychopharmacol. 2024. PMID: 38289825 Free PMC article.
Whole proteome mapping of compound-protein interactions.
Chirasani VR, Wang J, Sha C, Raup-Konsavage W, Vrana K, Dokholyan NV. Chirasani VR, et al. Curr Res Chem Biol. 2022;2:100035. doi: 10.1016/j.crchbi.2022.100035. Epub 2022 Sep 12. Curr Res Chem Biol. 2022. PMID: 38125869 Free PMC article.
New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay.
McConnachie L, Goadsby PJ, Vann RE, Ray S, Shrewsbury SB, Aurora SK. McConnachie L, et al. Front Neurol. 2023 Nov 21;14:1282846. doi: 10.3389/fneur.2023.1282846. eCollection 2023. Front Neurol. 2023. PMID: 38073648 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information